Life Sciences Archive » May, 2009

Life Sciences - May, 2009

154 articles

• Investor's $70M Suit V. Abbott Sent To Arbitration
• Centocor's Simponi May Cause Fatal Infections: FDA
• Unigen Founder Ordered To Testify In Seroctin IP Suit
• FTC, Wholesalers Amend AndroGel Complaints
• Aventis To Pay $96M To End Medicaid Rebate Probe
• Inequitable Conduct Still A Thorny Issue
• $4.7B Express Scripts-NextRX Merger Accelerates
• New Lexapro Class Action Can't Tag Onto MDL
• Boehringer Loses Bid To Appeal Reps' FLSA Status
• FTC Moves To Squash $3.1B CLS-Talecris Merger
• Stiefel Hits KV With Patent Suit Over Acne Gel
• USPTO Grants Re-Exam Of Merck Singulair Patent
• Merchant & Gould Nabs 5 IP Pros For New Wis. Office
• J&J Seeks To Reclaim Schering's Arthritis Drug Rights
• In The Wake Of Bilski
• AstraZeneca Sued For $1.3B Over Failed Drug Deal
• 1 Type Of GE Ultrasound Infringes SonoSite IP: Court
• Failure To Show Injury Dooms ERISA Suit V. Medtronic
• Whistleblower Claims Over Lipitor Marketing Tossed
• Ex-Cardinal Health Officers Settle SEC Fraud Charge
• Centocor Patents Stand In Fight Over Abbott's Humira
• High Court Jurist — Time For Real-World IP Focus
• FTC Will Push To Block $3.1B CSL-Talecris Merger
• Q&A With Paul Hastings' Joseph O'Malley
• Medtronic Trade Secrets Suit Against Nova Lives On
• SkinMedica Sues Histogen Over Anti-Aging Patent
• Q&A With Weil Gotshal's Nicholas Groombridge
• Lead Plaintiff Chosen In Medtronic Securities Suit
• GSK Argues Outside Sales Exemption In OT Suit
• High Court To Hear Merck Bid In Vioxx Class Action
• Cardiologist's IP Suit V. Medtronic Gets Go-Ahead
• FDA Puts The Kibosh On Distracting Drug Ads
• Q&A With O'Melveny & Myers' Richard Goetz
• Biovail, Melnyk Reach Proxy Deal Ahead Of Powwow
• Q&A With Greenberg Traurig's Lori Cohen
• Most Claims Survive In Royalty Spat Over HPV Drug
• 1st Seroquel Trial Plaintiff Fails To Prove Causation
• Fed. Circ. Orders Transfer of Sanofi Patent Suit
• Teva Targets Amgen Over Kidney Drug
• Ala. Scores $89M In Drug Co. Medicaid Fraud Case
• Judge Finds No Direct Infringement In Strattera Suit
• Doctor's Insider Trading Suit Moves Toward Trial
• Medtronic Updates Stent Report Targeting Abbott
• Johnson & Johnson Aims To Regain Remicade Rights
• Investor Suit Against Dendreon Can Proceed
• Cobalt Strikes Back At Pfizer In Lyrica Patent Spat
• Seroquel Docs Implicate AstraZeneca Execs: Attys
• Solvay, Unimed Sued Again Over AndroGel Deals
• Sanofi Uroxatral Claim Construction Gets Judge's Nod
• Apotex Enjoined From Launching Generic Pulmicort
• MIT, E8 Sue Navigenics Over Genetic Testing Patent
• Defendant In J&J Counterfeit Suit Agrees To Judgment
• Par Claims Rival Misled Patients With Nasal Spray
• Amended Complaint Merges Medicis Investors' Claims
• Medical Co. Asks Judge To Muzzle Greenberg Traurig
• Judge Blasts Plaintiffs' Lawyer In Guidant MDL
• EU Court Upholds Limits On Pharmacy Ownership
• Sens. Push To Bring Tobacco Under FDA Oversight
• Apotex Antitrust Claims Tossed From Daiichi IP Spat
• Baby Care Cos. Face Action Over Unlisted Toxins
• Fed Circ. Sets Product-By-Process Patent Restrictions
• Guidant Sues Rival, Ex-Workers Over Exodus
• Abbott Loses Bid For Judgment In $200M Stent Case
• FDA Lovenox Ruling Key To Competition Claims: Judge
• DOJ, States Join Whistleblower Suits V. Wyeth
• Onyx Sues Partner Bayer Over New Cancer Treatment
• Fed. Circ. Nixes Autogenomics Patent Suit Appeal
• Genzyme Sues Lupin Over Generic Renvela Plans
• 3rd Parties Again Denied Class Cert. In Neurontin Suit
• USPTO Rules On Stem Cell Patents In Biotech Battle
• The FTC, Reverse Payments In The Obama Era
• Lehman Ex-Sales Rep Pleads Guilty To Trading Scam
• Teva, Sun Still Free To Make Generic Protonix
• Pharmacies Join Clamor Over CVS-Caremark Merger
• Summary Judgment Denied In Humira Patent Case
• Pfizer To Pay $75M In Nigerian Meningitis Case
• Pharma Group Takes Swipe At EU Antitrust Probe
• Medtronic Execs Shake Off Shareholder's Claims
• Fed. Circ. Upholds P&G's Actonel Patent
• Mylan Didn't Infringe Invalid Mirapex Patent: Judge
• FDA Warns Sanofi Over Taxotere Marketing Claims
• Teva, Zydus Reach Settlement Over Coreg Patents
• Myriad Gene Patents Invalid, Unconstitutional: ACLU
• Connetics Shareholders Win Class Certification
• AAI Calls For Hard Look At Benefits Cos.' Merger
• Expert Witness Can't Testify in Zyprexa MDL: Judge
• VPX Wants Muscle Drink On Shelves Pending Appeal
• Willfulness Claim Pared From Whitening Patent Suit
• 8th Circ. Last Hope For Medtronic MDL Plaintiffs
• Understanding The Effects Of In Re Kubin
• Vt. High Court Says Pets Not Family In Eyes Of Law
• Wis. AG Seeks $212M Forfeiture From Pfizer Unit
• Sanofi-Aventis Suit Stayed For Genentech Petition
• Parents Target Lilly's Strattera In Negligence Suit
• New Antitrust Enforcement — Buckle Your Seatbelts
• Reckitt Benckiser Sues Watson Again Over Mucinex
• Merck Seeks To Boot Fosamax Plaintiffs, Experts
• Biomet Reaches Deals In 24 W.Va. Negligence Suits
• Novo Nordisk To Pay $18M In Oil-For-Food Cases
• Plaintiffs Protest $45M Becton Dickinson Settlement
• AstraZeneca Asserts New Patent In Pulmicort Suit
• Ex-Enzo Biochem Honcho Wants $10M Under SOX
• Judge Holds Off On Class Cert. In Drug Price Suit
• US House Lawmakers Weigh Bill To Overturn Riegel
• Plaintiffs Lose Bid For Judgment In Vioxx ERISA MDL
• 'Baseless' Shareholder Action V. Biovail Tossed
• Medtronic To Pay J&J $270M Over Stent Patent Fees
• Bavarian Nordic IP Suit Over Cancer Vaccine Lives
• Plaintiffs Add Damages Claims To Bayer Aspirin Suit
• Ex-Paul Hastings Tax Atty Cops To Insider Trading
• TRO Denied In Baby Formula False Advertising Spat
• Calif. Vioxx Users Denied Class Status
• 8 Simple Rules For A Successful Direct Exam
• State Lawmakers Call For FTC To Probe CVS Caremark
• FDA Calls For Black Box Warnings On AndroGel, Testim
• Novartis Loses Bid To End Wyeth ReFacto Patent Suit
• Forest Loses Bid To Limit Liability In Citalopram IP Suit
• SC Wins Return Of Seroquel Suit To State Court
• Testimony Tying Suicide, Pfizer Epilepsy Drug OK'd
• Orion, Wockhardt Strike Deal Over Parkinson's Drugs
• Thermo Fisher Sued Over LED Spectroscopy Patent
• FDA Asks For $510M To Tighten Food, Drug Safety
• Hydroxycut Class Actions Filed In Mass., Ala.
• Riegel Preempts Conn. Defibrillator Suit: Court
• Antitrust Enforcement Under Obama
• GSK To Sell Wellbutrin In US To Biovail For $510M
• Senior Competition Deputy Director To Leave FTC
• Biosite Inc. Recalls Cardiac Marker Test
• Biotech Co. May Face Ch. 7 Without DIP Loan
• 9th Circ. Seeks Clarity On Calif. Sales Reps' OT Status
• Preemption Pivotal To Medical Device Sector: Paper
• Wyeth Hits Sun, Caraco With False Advertising Suit
• DOJ Subpoenas J&J Unit In Reagents Antitrust Probe
• 3rd Circ. Remands AstraZeneca Preemption Case
• NJ, Synthes Settle Over Financial Disclosures
• Warner Chilcott Sues Mylan Again Over Doryx ANDA
• Illumina Sues Affymetrix Over Genetic Tech Patent
• Lilly Loses Bid To Force Discovery In Zyprexa MDL
• FDA Tells Baxter To Tone Down Tisseel Marketing
• Covington Hires Food And Drug Co-Chair From FDA
• FDA Warns P&G Over Contamination Risk At Plant
• Loss Causation Experts After Dura
• Abbott Opens Fire On J&J Unit Over Humira Patent
• 2-Year Patent Extension For Levaquin Sticks
• Nonparties Can't Help Class In Sanofi Suit: Judge
• Sepracor Lied To USPTO In Lunesta Patent App: Suit
• What's Next For Stem Cells?
• Sequenom Faces Suit Over Mishandled Test Data
• Conn.'s Deposition Requests Limited In Zyprexa MDL
• Efficient Recall System Can Save Big Trouble: Experts
• Wyeth Wants Howrey Nixed As Boston Sci Counsel
• Biovail, GSK Want Wellbutrin Antitrust Suit Tossed
• GINA's Impact On Clinical Research Trials
• Applera Wins Fees In Calif. Appeal Over DNA Patent